Skip to main content Skip to search Skip to main navigation

EU-MDR: European Parliament Votes in Favour of New Transition Periods

On 16 February 2023, the European Parliament voted positively to extend the deadline for the certification of medical devices under the EU Medical Devices Regulation (MDR). In January, the deadline extension was proposed by the European Commission to prevent massive supply shortages. Not enough Notified Bodies are available for the recertification of many medical devices, as a requirement of the MDR.

What will be amended?

These certification deadlines for manufacturers are staggered according to a risk-based approach:

  • For custom-made implantable devices in class III: until 26 May 2026.
  • For higher-risk devices: until 31 December 2027. This includes Class III devices and Class IIb implantable devices, excluding sutures, braces, dental fillings, dental braces, dental crowns, screws, wedges, plates, wires, pins, clips, and connectors.
  • For medium and lower risk products: until 31 December 2028. This includes other class IIb products, class IIa products, and products of classes ls, lm, lr.

The recent decision has dropped the sell-off deadline for all medical devices specified in the MDR/IVDR. This prevents products that have already been placed on the market and are still available in the trade from having to be withdrawn from the market.

The next official step for the amendment of the MDR/IVDR is the signing and subsequent publication in the Official Journal. On that day, the draft regulation will then enter into force.


EC: Proposal for amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional
provisions for certain medical devices and in vitro diagnostic medical devices

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

How is First Air Verified and Monitored During Aseptic Process Qualification?

How is First Air Verified and Monitored During Aseptic Process Qualification?

Here's the answer:
Read more
Outsourced Activities in the GDP Environment Part I: Supplier Management

Outsourced Activities in the GDP Environment Part I: Supplier Management

Supplier management is the systematic management of a company´s relationship with its suppliers. It encompasses supplier qualification and customer audits as described in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
FDA: Draft Guidance on Assessing Container Closure Systems for Drugs and Biologics

FDA: Draft Guidance on Assessing Container Closure Systems for Drugs and Biologics

On 14 August 2026, the US Food and Drug Administration (FDA) announced the publication of a new draft guidance document entitled ‘Container Closure Systems for Human Drugs and Biological Products’.

Read more
FDA: New FDA Commissioner Dr. Heidi Overton

FDA: New FDA Commissioner Dr. Heidi Overton

President Donald Trump has named White House aide Heidi Overton to lead the US Food and Drug Administration (FDA). Overton will fill the position previously held by Marty Makary, who left the agency in May. This announcement was made on Trump's Truth Social account on 19 August. Her nomination is subject to confirmation by the Senate.

Read more
IPEC: Stability Guide for Excipients has been Updated

IPEC: Stability Guide for Excipients has been Updated

The IPEC Stability Guide for Pharmaceutical Excipients has been updated and is now available as version 3 (2026), as announced on the IPEC (International Pharmaceutical Excipients Council) website.

Read more
EU: “Forever Chemicals” in a Conflict of Interests

EU: “Forever Chemicals” in a Conflict of Interests

On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.

Read more
Previous
Next